Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Y-mAbs Therapeutics stock had an average target of $13.91, with a low estimate of $7.00 and a high estimate of $23.
Price Target: $13.91 (+61.56%)
Analyst Consensus: Buy
Price Target
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock from 10 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
No data available
| Rating | Oct 2026 |
|---|---|
| Strong Buy | n/a |
| Buy | n/a |
| Hold | n/a |
| Sell | n/a |
| Strong Sell | n/a |
| Total | n/a |
Financial Forecast
Revenue This Year
84.47M
from 87.69M
Decreased by -3.67%
Revenue Next Year
96.27M
from 84.47M
Increased by 13.97%
EPS This Year
-0.84
from -0.67
EPS Next Year
-0.95
from -0.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 91.0M | 136.3M | |||
| Avg | 84.5M | 96.3M | |||
| Low | 77.7M | 84.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.8% | 61.3% | |||
| Avg | -3.7% | 14.0% | |||
| Low | -11.4% | -0.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.43 | -0.83 | |||
| Avg | -0.84 | -0.95 | |||
| Low | -1.14 | -1.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |